News about "Glenmark Pharmaceuticals"

Glenmark Pharmaceuticals Launches Olanzapine for Injection 10 mg/vial Single-Dose Vial in US

Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection 10 mg/vial, a bioequivalent and therapeutically equivalent generic to Zyprexa IntraMuscular Injection.

Glenmark Pharmaceuticals | 06/07/2026 | By Akanki

Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.

Glenmark Pharmaceuticals | 04/07/2026 | By News Bureau

Glenmark Pharma Receives Six Procedural Observations Following US FDA Inspection of Goa Facility

Glenmark Pharmaceuticals has received six procedural observations in a Form 483 following a US FDA GMP inspection of its Goa manufacturing facility. The company said there were no data integrity or repeat observations and expects no impact on the supply of its commercial products while it works with the regulator to address the findings.

Glenmark Pharmaceuticals | 02/07/2026 | By News Bureau |  313

Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer

Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.

Glenmark Pharmaceuticals | 02/07/2026 | By News Bureau

Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL

Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.

Glenmark Pharmaceuticals | 17/06/2026 | By News Bureau

Glenmark Launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), a bioequivalent and therapeutically equivalent generic version of Vimpat Injection.

Glenmark Pharmaceuticals | 05/06/2026 | By News Bureau

Glenmark Pharmaceuticals Launches Vancomycin for Injection USP in US

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP in the US market, expanding its injectable portfolio in a segment valued at nearly USD 37.9 million annually.

Glenmark Pharmaceuticals | 18/05/2026 | By News Bureau

Glenmark Takes Charge of RYALTRIS Commercialisation in US

Glenmark will handle end-to-end commercialisation and distribution of RYALTRIS nasal spray in the US, strengthening its respiratory portfolio presence.

Glenmark Pharmaceuticals | 06/04/2026 | By News Bureau |  297

Glenmark Pharma USA Launches Generic Milnacipran Tablets

Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.

Glenmark Pharmaceuticals | 20/03/2026 | By News Bureau |  119

Glenmark Pharma USA Introduces Potassium Phosphates Injection USP

Glenmark Pharmaceuticals USA is set to launch Potassium Phosphates Injection USP in March 2026.

Glenmark Pharmaceuticals | 19/03/2026 | By News Bureau